Skip to main content

Advertisement

Table 1 Characteristics of DRMAs with protocol registration or development and matched controls

From: Protocol registration or development may benefit the design, conduct and reporting of dose-response meta-analysis: empirical evidence from a literature survey

Basic information Total sample (N = 135) P value
Registered (n = 45) Matched (n = 90)
Author number [median (IQR)] 8 (7 to 9) 5 (3 to 8) <  0.01
 > = 6 38 (84.44%) 43 (48.78%)  
 < 6 7 (15.56%) 47 (52.22%)  
Regions*
 Asian 10 (22.22%) 20 (22.22%) Reference
 European 32 (71.11%) 44 (48.89%) ≈1
 America 3 (6.67%) 25 (27.78%)
 Australia 0 (0.00%) 1 (2.22%)
Database searched [median (IQR)] 3 (2 to 7) 2 (2 to 3) 0.52
 > = 2 36 (80.00%) 76 (84.44%)  
 < 2 9 (20.00%) 14 (15.56%)  
Funding    0.88
 Yes 38 (84.44%) 63 (70.00%)  
 No 4 (8.89%) 6 (6.67%)  
 Not reported 3 (6.67%) 21 (23.33%)
Journal type    0.60
 General journal 7 (15.56%) 11 (12.22%)  
 Specialist journal 38 (84.44%) 79 (87.78%)  
Publish year*    0.6
 2011–2013 18 (40.00%) 32 (35.56%)  
 2014–2016 15 (33.33%) 38 (42.22%)  
 2017~ 12 (26.67%) 20 (22.22%)  
Use of reporting checklist
 Yes 36 56 0.02
 No 9 34  
The score of AMSTAR [median (IQR)] 9 (8 to 11) 9 (7 to 10)
The score of PRISMA [median (IQR)] 22 (22 to 23) 22 (21 to 24)
  1. A general journal means it published articles on all areas (e.g. plos one) or focus on whole medicine area (e.g. BMJ open). For specialist journal, we treat it as those publish articles only on a certain type of disease (e.g. cancer) or a certain body system (e.g. urology)
  2. IQR Interquartile range
  3. *Regions (Asian versus Non-Asian) and publish year were matched variables by propensity score